Monoferric denied as experimental or investigational by Aetna?

Aetna's specific coverage criteria for monoferric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denied Monoferric as Experimental

Monoferric (ferric derisomaltose) received FDA approval for intravenous treatment of iron deficiency anemia in adults. An experimental or investigational denial from Aetna typically means either that Aetna's clinical policy has not yet categorized Monoferric as an established standard of care for your specific indication, or that Monoferric is approved but your particular diagnosis or clinical context falls outside what Aetna's policy currently designates as a covered use. This classification does not reflect the FDA's determination — FDA approval and a payer's "established" or "non-experimental" classification are separate standards.

## Why This Denial Is Appealable

Monoferric is FDA-approved for intravenous treatment of iron deficiency anemia in adults, and intravenous iron therapy broadly is a well-established treatment supported by major guideline organizations across multiple specialties (nephrology, gastroenterology, cardiology, and others). If Aetna's experimental classification conflicts with the FDA approval status or with relevant society guidelines, that conflict is the core of a strong appeal. Independent external reviewers apply generally accepted clinical standards — not Aetna's internal policy — and FDA approval combined with guideline endorsement is typically sufficient to overcome an experimental classification.

## Federal Appeal Framework

• Internal appeal: File within 180 days of the denial notice. Aetna must decide within 30 days (pre-service) or 60 days (post-service).
• External review (ACA §2719 / ERISA §503): Experimental/investigational denials are expressly eligible for independent external review under the ACA. Request external review within approximately four months of the final internal denial. An accredited Independent Review Organization will apply generally accepted standards of care.
• Expedited review: If delay would seriously jeopardize your health, request expedited review — typically decided within 72 hours.

## Documentation to Gather

1. FDA approval confirmation: The current FDA labeling for Monoferric confirming its approved indication for iron deficiency anemia in adults — publicly available from the FDA drug database (Prescribing Information). 2. Diagnosis and lab documentation: Records confirming your iron deficiency anemia diagnosis and the underlying condition, with laboratory findings consistent with the clinical picture. 3. Guideline support: A prescriber letter referencing the relevant guideline organization(s) for your specific underlying condition (e.g., nephrology, cardiology, gastroenterology, or hematology society guidelines) that endorse IV iron therapy for your patient population. 4. Oral iron inadequacy: Documentation that oral iron is not appropriate for your situation — whether due to intolerance, malabsorption, contraindication, or disease-related limitations on oral absorption. 5. Prescriber medical-necessity letter: A letter from your treating physician explaining why IV iron — and Monoferric specifically, if other IV iron products were inadequate or unsuitable — meets accepted standards of care for your diagnosis.

## Criteria-Mapping Structure

Request Aetna's clinical policy for IV iron therapy and the FDA prescribing information. Map each:

| Aetna Criterion / Basis for Denial | Rebuttal Evidence | Document | |---|---|---| | Drug classified as experimental | FDA approval in effect for iron deficiency anemia in adults | FDA PI cover + indication section | | Use outside guideline-supported population | Prescriber cites relevant society guideline organization | Prescriber letter | | Oral iron not trialed or failed | Trial history or contraindication documented | Chart notes + med history | | Diagnosis confirmed | Lab results + clinical diagnosis | Lab report + office notes | | Standard of care established | Guideline organization endorses IV iron for this population | Prescriber letter with citation |

An IRO reviewing this denial will compare Aetna's experimental classification against the FDA label and society guidelines — the combination of FDA approval and guideline support is typically decisive.